Sign up USA
Proactive Investors - Run By Investors For Investors

Namaste Technologies builds UK medical cannabis footprint with acquisition of pharma distributor AF Trading

The C$5mln acquisition will give Namaste access to a 30,000 square-foot distribution facility in the UK
Medical cannabis and a bottle of oil
Namaste’s subsidiary CannMmart Inc offers medical cannabis and oils through its e-commerce platform in Canada

Vancouver-based Namaste Technologies Inc (CVE:N, OCTMKTS:NXTFF) said Thursday that its wholly owned subsidiary, Namaste Bahamas will acquire UK-based AF Trading Ltd, which operates as Access Fulfillment, for C$5mln.

No capital-raise will be required as Access Fulfillment will receive half the payment in cash and the rest in Namaste stock. In exchange, Access Fulfillment will operate as Namaste's distribution center for CBD, or cannabidiol, a compound found in the hemp or cannabis plant that apparently helps with sleep and anxiety, and cannabis products in the United Kingdom.

Access Fulfillment operates a 30,000 square-foot distribution facility in the UK and holds a license to distribute pharmaceutical products.  

The British acquisition will help Namaste develop its medical cannabis distribution platform in the UK. Access Fulfillment's management will sign consulting agreements for operations and business development, said the company.

READ: Namaste Technologies inks deal with BlueSky Biologicals to distribute CBD products in the UK and Europe

Namaste said it intends to launch a platform styled on its Canadian subsidiary CannMart Inc within the UK market to “help monetize on its database of over 500,000 customers.” CannMart engages in the distribution of medical cannabis and oils through an e-commerce site in Canada.  

In July this year, UK Home Secretary Sajid Javid allowed doctors for the first time to prescribe cannabis-derived medicines to patients, as an alternative to prescription drugs. It followed high-profile campaigns which captured widespread media attention and evoked deep public sympathy.  

Campaigners had questioned how epileptic children could be prevented from accessing medicines that significantly improved their condition while the UK remained the world’s largest exporter of medicinal cannabis.

With the change of heart in UK, Namaste Technologies has inked a deal with BlueSky Biologicals Inc to distribute their hemp-derived cannabidiol products in the United Kingdom and Europe.

Namaste also operates an online platform that markets cannabis-related products like vaporizers and smoking accessories in 20 countries and via 30 websites.

The company also maintains a database of over 1.5 million customers and has acquired and NamasteMD, Canada's first fully integrated patient consultation portal available in the Apple and Google Play stores. 

Namaste shares were down nearly 6% to US$2.52 in afternoon trading.

Contact Uttara Choudhury at [email protected]

Follow her on Twitter@UttaraProactive 

View full N profile View Profile

Namaste Technologies Inc Timeline

Related Articles

August 22 2018
So far, the hit rate is a five out of 12 success rate for its investments
test tubes
September 11 2018
Sierra Oncology is about to start the third trial of Sareum’s SRA737 Chk1 inhibitor, while internally, Sareum is making “good progress” with its TYK2 inhibitor programme
scientist in lab
September 07 2018
Normally, patients have to wait until regulators have approved a drug before they get access to it, but up to 500 lupus sufferers will receive Lupuzor as part of a Managed Access Programme

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright ©, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use